Suppr超能文献

中国文化渗透于帕金森病治疗中的研究:一项在中国四个地区开展的横断面研究

Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China.

作者信息

Zhang Zhen-Xin, Chen Honglei, Chen Sheng-Di, Shao Ming, Sun Sheng-Gang, Qu Qiu-Min, Zhang Bao-Rong, Liu Yi-Ming, Xu Qun, Wan Xia, Li Ling, Wen Hong-Bo, Chen Xia, Chen Hai-Bo, Liu Zhen-Guo, Wang Jian, Wang Gang

机构信息

Departments of Neurology, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Wanfujing, Beijing 100730, China.

出版信息

BMC Res Notes. 2014 Jan 30;7:65. doi: 10.1186/1756-0500-7-65.

Abstract

BACKGROUND

Little is known about the clinical features and treatment of Chinese patients with Parkinson disease (PD).

METHODS

A large cross-sectional survey of clinical features, medication use, and motor complications was conducted in 901 consecutive PD patients, from 42 randomly selected university-affiliated hospitals in four urban economic regions of China, between December 2006 and May 2007.

RESULTS

The 901 PD patients had age range 30 to 88, and median disease duration 50 months. Most (737, 81.8%) used L-dopa (median 375 mg/day), and often added low doses of other antiparkinsonian agents. Among L-dopa-treated patients, the prevalence of motor complications was low (dyskinesias: 8.5%; motor fluctuations: 18.6%), even among patients with disease duration ≥11 years (dyskinesias: 18.1%; motor fluctuations: 42.2%). Higher L-dopa use was associated with higher occurrence of dyskinesias (OR 2.44; 95% CI 1.20-5.13) and motor fluctuations (OR 2.48; 95% CI 1.49-4.14). Initiating PD treatment with L-dopa alone (OR 0.46; 95% CI 0.22-0.95) or in combination with other medications (OR 0.41; 95% CI 0.19-0.87) was associated with less dyskinesia than treatment initiated with non-L-dopa medication.

CONCLUSIONS

Many Chinese PD patients are treated with low-dose L-dopa and added low-dose antiparkinsonian agents, with a low prevalence of motor complications, which might be influenced by Chinese culture.

摘要

背景

对于中国帕金森病(PD)患者的临床特征及治疗情况,人们了解甚少。

方法

2006年12月至2007年5月期间,对来自中国四个城市经济区42家随机选取的大学附属医院的901例连续的PD患者进行了一项关于临床特征、用药情况及运动并发症的大型横断面调查。

结果

901例PD患者年龄范围为30至88岁,疾病中位病程为50个月。大多数患者(737例,81.8%)使用左旋多巴(中位剂量为375毫克/天),并常加用低剂量的其他抗帕金森病药物。在接受左旋多巴治疗的患者中,运动并发症的发生率较低(异动症:8.5%;运动波动:18.6%),即使在病程≥11年的患者中也是如此(异动症:18.1%;运动波动:42.2%)。较高的左旋多巴使用量与异动症(比值比2.44;95%置信区间1.20 - 5.13)和运动波动(比值比2.48;95%置信区间1.49 - 4.14)的较高发生率相关。单独使用左旋多巴(比值比0.46;95%置信区间0.22 - 0.95)或与其他药物联合使用(比值比0.41;95%置信区间0.19 - 0.87)开始帕金森病治疗,与使用非左旋多巴药物开始治疗相比,异动症较少。

结论

许多中国帕金森病患者接受低剂量左旋多巴及加用低剂量抗帕金森病药物治疗,运动并发症发生率较低,这可能受中国文化影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85e0/3928922/6c7acb3c9142/1756-0500-7-65-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验